mortality, volumetry was used for the measurement. For the adjustment of body size differences, retroperitoneal hematoma volume was divided by the abdominal cavity volume, and the calculated ratio was used for the validation under appropriate statistical methods.
IP033.

Incidence of Thoracic Aortic Pathology on Low-Dose Computed Tomography Scans Done for Lung Cancer Screening
Micah Girotti, Michael Shockley, Mark Eskandari, Eric Hart, Tadaki Tomita. Northwestern University, Chicago, Ill
Objectives: Currently there is no approved thoracic aortic aneurysm (TAA) screening protocol as exists for the abdominal aorta. However, as a result of the National Lung Screening Trial, the Centers for Medicare and Medicaid Services (CMS) recently began covering annual low-dose computed tomography (LDCT) scans in long-term smokers, a population also at risk for developing aortic aneurysms. We hypothesized that these lung cancer screening scans represent a novel method of identifying TAA.
Methods: We identified 300 consecutive patients undergoing LDCT for lung cancer screening between the years 2014 and 2015 at a single center. Patient records were reviewed, and demographics and comorbidities were recorded. Each CT scan was reviewed, and the dimensions of the thoracic aorta were measured in three locations: immediately distal to the left subclavian artery, the middescending thoracic aorta, and immediately proximal to the celiac artery. We defined aortic ectasia as having a thoracic aortic diameter measuring between 3.5 and 4.0 cm, and aneurysm as measuring >4.0 cm.
Results: In total, 300 patients (157 [52%] men) were examined. The mean age was 61.6 years (range 43-78). There were 298 (99.3%) with a smoking history, with 141 (47%) being active smokers at the time of their initial scan. Common comorbidities included hyperlipidemia in 113 (37%), hypertension in 100 (33.3%), and chronic obstructive pulmonary disease in 37 (12.3%). Four patients (1.3%) had a personal history of abdominal aortic aneurysm (AAA): two had been repaired previously and two did not yet meet criteria for repair. There were 11 patients (4%) with a family history of AAA. Of the patients undergoing lung cancer screening, 166 (55.3%) met CMS criteria for AAA screening duplex. Overall, 11 patients (4%) had thoracic aortic ectasia, and one patient had a small distal TAA measuring 4.01 cm. The mean diameter of the aorta at the left subclavian artery in the population was 2.80 cm, 2.65 cm in the midthorax, and 2.59 cm at the celiac artery.
Conclusions: LDCT for lung cancer examines a population similar to that at risk for aortic aneurysm, with over half of the population in this sample meeting CMS criteria for AAA duplex screening. The thoracic aorta can be measured with acceptable accuracy on these scans. Overall, there is a low incidence of TAA in this population. Larger studies will need to be done to determine the impact of these scans on the diagnosis of thoracic aortic pathology.
Author Disclosures: M. Eskandari: Nothing to disclose; M. Girotti: Nothing to disclose; E. Hart: Nothing to disclose; M. Shockley: Nothing to disclose; T. Tomita: Nothing to disclose. Methods: A single-center study, approved by the Institutional Review Board, was retrospectively conducted on a prospectively compiled, (Table) . The outcome measures were technical and clinical success. Clinical success was defined as improvement in ankle-brachial index (ABI) and in Rutherford classes (RC). Immediate (30-day) and midterm patency, AAA exclusion, major adverse events (MAE), and mortality rates were also noted. Results: Seventeen patients (80.9%) were male, and mean age was 73.6 6 6.4 years. Mean preoperative ABI was 0.45 6 0.14. RC at baseline was 2 in 4 patients, 3 in 14, and 4 in the last 3. Four patients presented a CIA occlusion (19.1%), bilateral in one case (4.7%); detailed preoperative anatomical features are reported in the Table. Technical success was achieved in all cases. After AFX deployment, no reinforcing stent was implanted in CIA, while 18 EIAs presenting a stenosis >50% or a total occlusion required adjunctive self-expandable stent. One patient required a reintervention for closure device failure. At 30-day follow-up, no deaths, MAEs, or reinterventions were recorded. Patency of the AFX and iliac vessels was confirmed in all patients. Improvement in ABI was registered in all patients, mean value was 0.91 6 0.11. Mean follow-up time was 25.2 6 11.1 months, and 18 of 21 patients completed at least the 12-month follow-up. Primary patency was maintained in all cases. Two patients required a new endovascular procedure for a disease progression on the EIAs. No deaths or amputations occurred, while two patients sustained a myocardial infarction. ABI improvement from baseline was maintained (mean 0.88 6 0.13). Distribution in RC categories during study period is reported in the Fig. Conclusions: This is the largest study to examine the off-label use of the AFX unibody stent graft for the treatment of TASC-D AIOD with coexistent AAA. AFX stent graft appears to be a safe and effective solution for those complex lesions, as in case of isolated obstructive or aneurysmatic disease.
IP035.
Results of AFX Unibody Stent Graft Implantation in Patients Presenting
Author Disclosures: L. Capoccia: Nothing to disclose; M. Formiconi: Nothing to disclose; W. Mansour: Nothing to disclose; N. Montelione: Nothing to disclose; C. Pranteda: Nothing to disclose; P. Sirignano: Nothing to disclose; F. Speziale: Nothing to disclose. Objectives: The best-established strategies to treat type Ia endoleak after endovascular aneurysm repair (EVAR) are either increasing wall apposition of the endograft or extending the landing zone with extension cuffs, fenestrated cuffs, and chimney endografting. However, some patients are not suitable for such methods or present recurrence after those procedures. Aim of this study was to evaluate the effectiveness of embolization to treat type Ia endoleak post-EVAR in highly selected patients.
IP037.
Effectiveness of Aneurysm Sac Embolization for Type Ia Endoleak After Endovascular Aneurysm Repair
Methods: Between February 2011 and December 2016, 22 consecutive patients not eligible for either open surgery or complex endovascular repair underwent embolization of a type Ia endoleak post-EVAR at our institution. Society for Vascular Surgery Score was preoperatively performed to assess comorbidity severity. Primary end point was technical success, defined as the absence of type Ia endoleak in the completion angiography. Secondary end points were freedom from aneurysm-related reinterventions and freedom from sac enlargement.
Results: Five patients (22.7%) were symptomatic and four (18.2%) were admitted with a contained rupture of the aneurysm. Mean Society for Vascular Surgery Score was 8.1 6 2.6 (range, 4.0-12.0). The embolization of the endoleak was performed with liquid embolic agent in 12 patients (54.6%), with liquid embolic agent combined with coils and/or plugs in 5 patients (22.7%), and with coils and/or plugs in 5 patients (22.7%). Technical success at the completion angiography was 100%. The postoperative imaging revealed complete sealing of the aneurysm in 14 cases (63.6%). Reintervention-free survival rates at 6 and 12 months were 79.1% and 64.4%, respectively. Ten of 22 patients underwent follow-up by magnetic resonance or computed tomography scans. Freedom from sac enlargement was achieved in six (60%) of 10 patients at a mean follow-up of 14.2 months (range 2.5-33.5 months). Among four patients (40%) with sac enlargement, 1 was treated with fenestrated cuff, 2 were managed expectantly by planning a sac size control in 6 months, and 1 underwent an unsuccessful re-embolization procedure. Liquid embolic agent 4 100 <2 7 Liquid embolic agent 1 100 12
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